Mihaylova Violeta, Hantke Janina, Sinigerska Ivanka, Cherninkova Silvia, Raicheva Margarita, Bouwer Sonja, Tincheva Radka, Khuyomdziev Djako, Bertranpetit Jaume, Chandler David, Angelicheva Dora, Kremensky Ivo, Seeman Pavel, Tournev Ivailo, Kalaydjieva Luba
Department of Neurology, Medical University, Sofia, Bulgaria.
Brain. 2007 Apr;130(Pt 4):1050-61. doi: 10.1093/brain/awm026. Epub 2007 Mar 14.
Niemann-Pick disease (NPD), an autosomal recessive disorder resulting from mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene, is subdivided into the acute, lethal neuronopathic type A, and the chronic visceral type B, explained by the different residual activity levels of acid sphingomyelinase (ASMase). An increasing number of reports on intermediate forms, challenging this traditional clinical classification, have described a broad range of neurological manifestations; however genotype-phenotype correlations have been compromised by relatively small sample sizes and/or allelic heterogeneity. Here we present a genetically homogeneous group of 20 Gypsy patients with intermediate NPD, where we observed a surprising diversity of neurological features. All affected subjects were homozygous for the same ancestral mutation, W391G in SMPD1, yet displayed the entire spectrum of phenotypic variation observed previously in unrelated affected subjects of diverse ethnicity and disease-causing mutations, ranging from subclinical retinal involvement to severe ataxia, cognitive deficits and psychiatric disorders. The clinical heterogeneity of W391G homozygotes points to additional factors, beyond SMPD1 and residual ASMase, which determine the localization, extent and severity of neural involvement. The phenotype similarity of affected relatives suggests a possible role of genetic modifying factors. In practical terms, W391 is common in the Gypsy population and the diagnosis of NPD should be borne in mind despite the atypical course of the disease. Generally, our findings indicate that mutation analysis is of limited value in predicting brain damage, and the option of enzyme replacement therapy should be considered in intermediate NPD.
尼曼-匹克病(NPD)是一种常染色体隐性疾病,由鞘磷脂磷酸二酯酶1(SMPD1)基因突变引起,根据酸性鞘磷脂酶(ASMase)不同的残余活性水平,可细分为急性致死性神经病变A型和慢性内脏型B型。越来越多关于中间型的报道对这种传统临床分类提出了挑战,这些报道描述了广泛的神经学表现;然而,由于样本量相对较小和/或等位基因异质性,基因型-表型相关性受到了影响。在此,我们报告了一组基因同质的20名患有中间型NPD的吉普赛患者,我们在其中观察到了令人惊讶的神经学特征多样性。所有受影响的受试者对于SMPD1基因中相同的祖传突变W391G都是纯合子,但却表现出了先前在不同种族和致病突变的无关受影响受试者中观察到的全部表型变异范围,从亚临床视网膜受累到严重共济失调、认知缺陷和精神障碍。W391G纯合子的临床异质性表明,除了SMPD1和残余ASMase之外,还有其他因素决定神经受累的定位、程度和严重程度。受影响亲属的表型相似性表明遗传修饰因子可能发挥了作用。实际上,W391在吉普赛人群中很常见,尽管疾病过程不典型,但仍应考虑NPD的诊断。一般来说,我们的研究结果表明,突变分析在预测脑损伤方面价值有限,对于中间型NPD应考虑酶替代疗法。